SIGA - SIGA to activate first trial sites for monkeypox therapy in U.K. next week - Bloomberg
- SIGA Technologies ( NASDAQ: SIGA ), the maker of smallpox therapy TPOXX, plans to start clinical trials for its lead product, activating trial sites in the U.K. for the first-time next week to evaluate the treatment against the related monkeypox virus Bloomberg reported Wednesday.
- During an interview , SIGA's ( SIGA ) Chief Scientific Officer Dennis E. Hruby said that the U.K. studies would represent the first of a dozen clinical trial sites to be activated in the latest monkeypox outbreak, which has so far caused over 38,000 cases according to Our World in Data.
- The U.S. has reported more than 12,600 monkeypox cases as of Aug. 16, the data from the Centers for Disease Control and Prevention (CDC) indicates.
- TPOXX is currently available in the U.S. as a treatment for smallpox on a case-by-case basis under the FDA's Expanded Access program.
For further details see:
SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg